Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: ziprasidone hydrochloride

« Back to Dashboard

Summary for Generic Name: ziprasidone hydrochloride

Drug Master File Entries: see list19
Suppliers: see list10
Therapeutic Class:Antipsychotics
Bipolar Agents
Formulation / Manufacturing:see details

Pharmacology for Ingredient: ziprasidone hydrochloride

Clinical Trials for: ziprasidone hydrochloride

A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder
Status: Completed Condition: Major Depressive Disorder

Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome
Status: Completed Condition: Schizophrenia

An Investigation of Sleep Architecture in Ziprasidone-Treated Bipolar Depression
Status: Completed Condition: Depression, Bipolar

Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg Under Fasting Conditions
Status: Completed Condition: Healthy

Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Under Fed Conditions
Status: Completed Condition: Healthy

Geodon for the Treatment of Refractory Social Anxiety Disorder
Status: Completed Condition: Social Anxiety Disorder

Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder
Status: Terminated Condition: Generalized Anxiety Disorder; Bipolar Disorder

A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders
Status: Completed Condition: Schizophrenia; Bipolar Disorder; Schizoaffective Disorder

Ziprasidone in Pediatric Bipolar Disorder
Status: Completed Condition: Bipolar Disorder

Treatment of Major Depressive Disorder (MDD) With Ziprasidone
Status: Completed Condition: Depression

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Inc
ziprasidone hydrochloride
SUSPENSION;ORAL021483Mar 29, 2006RXYes6,150,366<disabled>Y<disabled>
Mylan Pharms Inc
ziprasidone hydrochloride
CAPSULE;ORAL202395Oct 10, 2013RXNo<disabled><disabled>
Wockhardt Ltd
ziprasidone hydrochloride
CAPSULE;ORAL090348Sep 5, 2012RXNo<disabled><disabled>
Pfizer Inc
ziprasidone hydrochloride
SUSPENSION;ORAL021483Mar 29, 2006RXYes6,245,766<disabled><disabled>
ziprasidone hydrochloride
CAPSULE;ORAL020825Feb 5, 2001RXYes6,150,366<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology